{"brief_title": "CPG 7909 Injection in Non-Small Cell Lung Cancer", "brief_summary": "Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every other treatment cycle until disease progression.", "condition": "Carcinoma, Non-Small Cell Lung", "intervention_type": "Drug", "intervention_name": "Chemotherapy", "description": "A taxane and a platinum compound given on week one of three-week cycles:\nRegimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6", "arm_group_label": "1", "other_name": "Paclitaxel (Taxol), docetaxel (TAXOTERE) cisplatin and carboplatin (e.g. PARAPLATIN)", "criteria": "Inclusion Criteria: - Histologically or cytologically confirmed non-small cell lung cancer that is beyond surgical cure or that is metastatic (Stage IIIB or IV according to AJCC). - Patients must have measurable disease according to the RECIST criteria. Exclusion Criteria: - Prior treatment with chemotherapy; patients may have received prior radiotherapy. - Patients with suspected or known CNS metastases.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00070629.xml"}